U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241468) titled 'An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease' on Nov. 14.
Brief Summary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Immune Nephropathy
Relapsed/Refractory Immune-mediated Kidney Disease
Intervention:
BIOLOGICAL: anti-CD19/BCMA U CAR T
To evaluate the safety and effect...